Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0015672 (fatigue)
 51,768 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We thank Chiche et al for their interest in our study. Sjogren's syndrome (SS) patients consistently report profound, debilitating fatigue as the single symptom which most severely decreases their quality of life. Although this information should inform drug development efforts, the voice of the patient has not been well represented in SS clinical trials. The primary endpoint in many of the clinical studies over the past decade have relied on the European Union Against Rheumatism (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI), which does not measure fatigue or dryness, the chief complaints of these patients.
 ...
PMID:Cytokines and Fatigue in Sjogren's Syndrome: An Evolving Landscape. 3316 38

We read with interest the study by Posada et al. (1) evaluating the therapeutic effects of RSLV-132 (a new RNase compound) in patients with primary Sjogren syndrome (pSS). At first glance, one may be surprised by the enthusiastic conclusion of authors in spite of a biological effect opposite to what was expected, namely an increased expression of interferon (IFN)-stimulated genes (ISG), while pSS is considered as an acquired interferonopathy. However, therapeutic trials are also a unique opportunity to learn about the pathogenesis of such complex condition. Indeed, this study showed a significant improvement of fatigue (measured by various validated scales) in treated patients, surprisingly correlated with the increased expression of ISG.
 ...
PMID:Should we finally consider the biopsychosocial model in systemic autoimmune diseases? 3316 42


<< Previous 1 2 3 4